BACE-1/Mpro-IN-1

BACE-1/Mpro-IN-1 is a high brain-penetrant BACE-1 (IC50 = 0.26 μM) and SARS-CoV-2 Mpro (IC50 = 0.91 μM) dual inhibitor. BACE-1/Mpro-IN-1 binds to the aspartyl protease and cysteine protease as a mixed-type inhibitor. BACE-1/Mpro-IN-1 exhibits the most favorable docking score and a strong interaction profile. BACE-1/Mpro-IN-1 can be used for the study of COVID-19 exacerbated Neuroinflammation and Alzheimer’s disease[1].

Product Specifications

UNSPSC

12352005

Target

Beta-secretase; SARS-CoV

Related Pathways

Anti-infection; Neuronal Signaling

Field of Research

Infection; Neurological Disease

Smiles

COC1=CC=C(C=C1)NC(C2=CC(C3=CC=CC=C3)=NC4=CC=C(C=C42)C5=CC=NC=C5)=O

Molecular Formula

C28H21N3O2

Molecular Weight

431.49

References & Citations

[1]Khan AH, et al. Mitigating SARS-CoV-2-exacerbated neuroinflammation and Alzheimer's pathology: Synthesis of quinoline-based dual inhibitors targeting cysteine and aspartyl proteases. Eur J Med Chem. 2025 Dec 15;300:118144.